Abbott (ABT) is experiencing strong growth in routine diagnostics owing to increased domestic and international demand. Within Established Pharmaceuticals (“EPD”), the company is driving robust growth in key therapeutic areas, advancing in the biosimilar strategy and establishing financial stability. However, the declining COVID-testing sales and currency fluctuations may restrict Abbott’s growth potential.In the past year, this Zacks Rank #3 (Hold) stock has increased 11.2% compared with the 15.5% rise of ...